Background Inoxitol hexakisphosphate (IP6) has been found to have an important role in biomineralization and a direct effect inhibiting mineralization of osteoblasts in vitro without impairing extracellular matrix production and expression of alkaline phosphatase. IP6 has been proposed to exhibit similar effects to those of bisphosphonates on bone resorption, however, its direct effect on osteoclasts (OCL) is presently unknown. Methodology/Principal Findings The aim of the present study was to investigate the effect of IP6 on the RAW 264.7 monocyte/macrophage mouse cell line and on human primary osteoclasts. On one hand, we show that IP6 decreases the osteoclastogenesis in RAW 264.7 cells induced by RANKL, without affecting cell proliferation or cell viability. The number of TRAP positive cells and mRNA levels of osteoclast markers such as TRAP, calcitonin receptor, cathepsin K and MMP-9 was decreased by IP6 on RANKL-treated cells. On the contrary, when giving IP6 to mature osteoclasts after RANKL treatment, a significant increase of bone resorption activity and TRAP mRNA levels was found. On the other hand, we show that 1 μM of IP6 inhibits osteoclastogenesis of human peripheral blood mononuclear cells (PBMNC) and their resorption activity both, when given to undifferentiated and to mature osteoclasts. Conclusions/Significance Our results demonstrate that IP6 inhibits osteoclastogenesis on human PBMNC and on the RAW264.7 cell line. Thus, IP6 may represent a novel type of selective inhibitor of osteoclasts and prove useful for the treatment of osteoporosis.
References
[1]
Irvine RF, Schell MJ (2001) Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol 2: 327–338.
[2]
Raboy V (2003) myo-Inositol–1,2,3,4,5,6-hexakisphosphat？e. Phytochemistry 64: 1033–1043.
[3]
Vallejo M, Jackson T, Lightman S, Hanley MR (1987) Occurrence and extracellular actions of inositol pentakis- and hexakisphosphate in mammalian brain. Nature 330: 656–658.
[4]
Bunce CM, French PJ, Allen P, Mountford JC, Moor B, et al. (1993) Comparison of the levels of inositol metabolites in transformed haemopoietic cells and their normal counterparts. Biochem J 289 (Pt 3): 667–673.
[5]
Grases F, Simonet BM, Prieto RM, March JG (2001) Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 86: 225–231.
[6]
Grases F, Simonet BM, Prieto RM, March JG (2001) Variation of InsP(4), InsP(5) and InsP(6) levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 12: 595–601.
[7]
Shamsuddin AM (1999) Metabolism and cellular functions of IP6: a review. Anticancer Res 19: 3733–3736.
[8]
Shamsuddin AM, Vucenik I, Cole KE (1997) IP6: a novel anti-cancer agent. Life Sci 61: 343–354.
[9]
Sasakawa N, Sharif M, Hanley MR (1995) Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. Biochem Pharmacol 50: 137–146.
[10]
Grases F, Costa-Bauza A (1999) Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res 19: 3717–3722.
Hawkins PT, Poyner DR, Jackson TR, Letcher AJ, Lander DA, et al. (1993) Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate. Biochem J 294 (Pt 3): 929–934.
[13]
York JD, Odom AR, Murphy R, Ives EB, Wente SR (1999) A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285: 96–100.
[14]
Shears SB (2001) Assessing the omnipotence of inositol hexakisphosphate. Cell Signal 13: 151–158.
[15]
Grases F, Ramis M, Costa-Bauza A (2000) Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 28: 136–140.
[16]
Grases F, Costa-Bauza A, March JG (1994) Artificial simulation of the early stages of renal stone formation. Br J Urol 74: 298–301.
[17]
Grases F, Prieto RM, Simonet BM, March JG (2000) Phytate prevents tissue calcifications in female rats. Biofactors 11: 171–177.
[18]
Grases F, Perello J, Prieto RM, Simonet BM, Torres JJ (2004) Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci 75: 11–19.
[19]
Grases F, Sanchis P, Costa-Bauza A, Bonnin O, Isern B, et al. (2008) Phytate inhibits bovine pericardium calcification in vitro. Cardiovasc Pathol 17: 139–145.
[20]
Grases F, Sanchis P, Perello J, Isern B, Prieto RM, et al. (2007) Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J 71: 1152–1156.
[21]
Magrill DS (1973) Phytate inhibition of enamel hardening by mineralizing solutions. J Dent Res 52: 1342.
[22]
Grases F, Isern B, Sanchis P, Perello J, Torres JJ, et al. (2007) Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 12: 2580–2587.
[23]
Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A (1998) Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 32: 261–265.
[24]
Grases F, Perello J, Sanchis P, Isern B, Prieto RM, et al. (2009) Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. J Periodontal Res 44: 616–621.
[25]
Grases F, Prieto RM, Sanchis P, Saus C, De Francisco T (2008) Role of phytate and osteopontin in the mechanism of soft tissue calcification. J Nephrol 21: 768–775.
[26]
Conte A, Piza P, Garcia-Raja A, Grases F, Costa-Bauza A, et al. (1999) Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol 52: 305–310.
[27]
Grases F, Sanchis P, Perello J, Isern B, Prieto RM, et al. (2006) Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci 11: 136–142.
[28]
Grases F, Sanchis P, Prieto RM, Perello J, Lopez-Gonzalez AA (2010) Effect of tetracalcium dimagnesium phytate on bone characteristics in ovariectomized rats. J Med Food 13: 1301–1306.
[29]
Lopez-Gonzalez AA, Grases F, Roca P, Mari B, Vicente-Herrero MT, et al. (2008) Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis. J Med Food 11: 747–752.
[30]
Lopez-Gonzalez AA, Grases F, Perello J, Tur F, Costa-Bauza A, et al. (2010) Phytate levels and bone parameters: a retrospective pilot clinical trial. Front Biosci (Elite Ed) 2: 1093–1098.
[31]
Addison WN, McKee MD (2010) Inositol hexakisphosphate inhibits mineralization of MC3T3-E1 osteoblast cultures. Bone 46: 1100–1107.
[32]
Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R (2004) Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2: 6.
[33]
Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285–290.
[34]
Roodman GD (1996) Advances in bone biology: the osteoclast. Endocr Rev 17: 308–332.
Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96: 3540–3545.
[37]
Yamamoto A, Miyazaki T, Kadono Y, Takayanagi H, Miura T, et al. (2002) Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res 17: 612–621.
[38]
Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, et al. (2002) Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22: 992–1000.
[39]
Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, et al. (2004) Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res 293: 292–301.
[40]
Komarova SV, Pereverzev A, Shum JW, Sims SM, Dixon SJ (2005) Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc Natl Acad Sci U S A 102: 2643–2648.
[41]
Shadduck RK, Waheed A, Mangan KF, Rosenfeld CS (1993) Preparation of a monoclonal antibody directed against the receptor for murine colony-stimulating factor-1. Exp Hematol 21: 515–520.
[42]
Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490–495.
[43]
Reszka AA, Rodan GA (2004) Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 4: 711–719.
[44]
Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20: 1291–1300.
[45]
Greiner S, Kadow-Romacker A, Wildemann B, Schwabe P, Schmidmaier G (2007) Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res A 83: 1184–1191.
[46]
Van Beek ER, Lowik CW, Papapoulos SE (2002) Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30: 64–70.
[47]
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, et al. (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478–1487.
[48]
Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692–2696.
[49]
Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27: 38–41.
[50]
Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, et al. (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22: 455–461.
[51]
Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B (2007) The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80: 769–775.
[52]
Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, et al. (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60: 6001–6007.
[53]
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, et al. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680–686.
[54]
Wilson SR, Peters C, Saftig P, Bromme D (2009) Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284: 2584–2592.
[55]
Zuo J, Jiang J, Chen SH, Vergara S, Gong Y, et al. (2006) Actin binding activity of subunit B of vacuolar H+-ATPase is involved in its targeting to ruffled membranes of osteoclasts. J Bone Miner Res 21: 714–721.
[56]
Blair HC, Borysenko CW, Villa A, Schlesinger PH, Kalla SE, et al. (2004) In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects. J Bone Miner Res 19: 1329–1338.
[57]
Samanna V, Ma T, Mak TW, Rogers M, Chellaiah MA (2007) Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. J Cell Physiol 213: 710–720.
[58]
Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, et al. (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333–342.
[59]
Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, et al. (1998) Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101: 1942–1950.
[60]
Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11: 150–159.
[61]
Toro EJ, Zuo J, Ostrov DA, Catalfamo D, Bradaschia-Correa V, et al.. (2012) Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem.
[62]
Menniti FS, Miller RN, Putney JW Jr, Shears SB (1993) Turnover of inositol polyphosphate pyrophosphates in pancreatoma cells. J Biol Chem 268: 3850–3856.
[63]
Stephens L, Radenberg T, Thiel U, Vogel G, Khoo KH, et al. (1993) The detection, purification, structural characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s). J Biol Chem 268: 4009–4015.
[64]
Shears SB (2004) How versatile are inositol phosphate kinases? Biochem J 377: 265–280.
[65]
Chakraborty A, Kim S, Snyder SH (2011) Inositol pyrophosphates as mammalian cell signals. Sci Signal 4: re1.
[66]
Vignery A (2005) Macrophage fusion: the making of osteoclasts and giant cells. J Exp Med 202: 337–340.
[67]
Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345–351.
